Piper Jaffray Cos. set a $24.00 target price on Audentes Therapeutics Inc (NASDAQ:BOLD) in a research note released on Monday. The firm currently has a a buy rating on the stock.
A number of other brokerages have also recently commented on BOLD. Cowen and Company assumed coverage on Audentes Therapeutics in a research note on Monday, August 15th. They set an outperform rating on the stock. Wedbush restated an outperform rating and set a $20.00 price objective on shares of Audentes Therapeutics in a research note on Thursday, September 1st.
Audentes Therapeutics (NASDAQ:BOLD) opened at 20.34 on Monday. The company’s 50-day moving average price is $16.19 and its 200-day moving average price is $15.65. The stock’s market cap is $441.89 million. Audentes Therapeutics has a 1-year low of $13.06 and a 1-year high of $20.74.
In related news, Director Orbimed Advisors Llc bought 33,334 shares of the stock in a transaction dated Monday, July 25th. The stock was bought at an average cost of $15.00 per share, with a total value of $500,010.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Versant Ventures Iv, Llc acquired 35,000 shares of the firm’s stock in a transaction that occurred on Monday, July 25th. The stock was acquired at an average cost of $15.00 per share, with a total value of $525,000.00. The disclosure for this purchase can be found here.
Audentes Therapeutics Company Profile